Brand Reference: Crestor
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rosuvastatin Calcium RxNorm Concept ID | 301542 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0520 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $86.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.70 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $6.50 / mo | 44 Zero-PHI Verified Patient Logs |
Hydrophilic sulfonamide statin selectively taken up into hepatocytes via OATP1B1 transporters where it competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, depleting intrahepatic sterol pools to upregulate SREBP-2 and hepatic LDL-receptor density—cutting ApoB by 40%–55%.
Across 44 community cost disclosures for Rosuvastatin Calcium (Crestor), cash buyers routing around $86.00 retail markups capture a 93% discount ($5.70/mo benchmark vs $0.0520 NADAC acquisition).
Following administration (5 mg PO daily (low-dose ApoB + ezetimibe combo)), Rosuvastatin Calcium achieves 20% oral bioavailability and 1–2 weeks initial; maximal apob reduction by week 4 onset, governed by a 19 hours terminal half-life through 90% excreted unchanged in feces; minimal (~10%) cyp2c9 metabolism, avoiding cyp3a4 drug interactions.
Before initiating Rosuvastatin Calcium at 5 mg PO daily (low-dose ApoB + ezetimibe combo), clinical safety checklists rule out active decompensated liver failure; concomitant cyclosporine or gemfibrozil. Logged tolerability patterns center on mild myalgia (8% of reports), fasting glucose +3 mg/dl (5% of reports), ck elevation (reversible) (3% of reports).
Across 44 verified cash-pay logs, Rosuvastatin Calcium achieves a 92.40% Worth-It rating with out-of-pocket spend averaging $6.50/mo versus $86.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO daily (low-dose ApoB + ezetimibe combo) for Rosuvastatin Calcium; monthly out-of-pocket dropped to $5.02 compared with $86.00 retail.
Completed 10 weeks on Rosuvastatin Calcium (10 mg PO daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 20 mg PO daily Rosuvastatin Calcium sourced via Local Pharmacy ($6.61/mo cash pay without insurance prior authorization).